Clinical Trials Browser

Phase 1/2 × Prostatic Neoplasms × Docetaxel × Clear all

NCT04633252 2026-01-16

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06568094 2025-12-31

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06615752 2025-11-12

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT03837353 2023-12-18

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Phase 1/2 Terminated

18 enrolled 15 charts

Prostatic Neoplasms

NCT02494921 2022-08-31

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Phase 1/2 Completed

43 enrolled 22 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02565901 2021-10-01

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

28 enrolled 8 charts

Prostatic Neoplasms

NCT01468532 2021-03-25

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

18 enrolled 15 charts

Prostatic Neoplasms

NCT01683994 2019-11-08

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Phase 1/2 Completed

49 enrolled 18 charts

Prostatic Neoplasms

NCT00456989 2019-10-30

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

Phase 1/2 Completed

39 enrolled 4 charts

Prostatic Neoplasms

NCT01084655 2019-07-30

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Completed

38 enrolled 29 charts

Prostatic Neoplasms

NCT00669162 2019-07-24

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Phase 1/2 Completed

27 enrolled 7 charts

Prostatic Neoplasms

NCT00225420 2017-06-01

NRR

Phase 1/2 Completed

23 enrolled 9 charts

Prostatic Neoplasms

NCT00879619 2017-02-01

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Phase 1/2 Terminated

4 enrolled 3 charts

Prostatic Neoplasms

NCT00861471 2016-06-30

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Phase 1/2 Terminated

24 enrolled 11 charts

Prostatic Neoplasms

NCT00503984 2016-06-09

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Phase 1/2 Terminated

22 enrolled 16 charts

Pain, Prostatic Neoplasms

NCT00459186 2016-05-16

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Phase 1/2 Completed

19 enrolled 6 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00514267 2015-08-13

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Phase 1/2 Completed

Neoplasms, Prostatic Neoplasms

NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Phase 1/2 Terminated

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00439270 2014-03-28

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Phase 1/2 Completed

49 enrolled 25 charts

Prostatic Neoplasms

NCT00002775 2014-01-06

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Phase 1/2 Unknown

Prostatic Neoplasms

NCT00003103 2013-07-03

Chemotherapy in Treating Patients With Solid Tumors

Phase 1/2 Completed

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Wilms Tumor, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00074022 2013-01-24

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

Phase 1/2 Completed

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

NCT00293371 2012-10-11

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

Phase 1/2 Terminated

Prostatic Neoplasms

NCT00448734 2009-01-21

A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer

Phase 1/2 Unknown

Neoplasm Metastasis, Prostatic Neoplasms

NCT00121095 2007-12-21

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

Phase 1/2 Unknown

Prostatic Neoplasms

NCT00283829 2007-11-29

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms

NCT00115635 2007-10-02

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms